Alberico L. Catapano
A5091523473- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Atherosclerosis and Cardiovascular Diseases
- Cholesterol and Lipid Metabolism
- Pharmaceutical Economics and Policy
- Lipid metabolism and disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Liver Disease Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Computational Drug Discovery Methods
- Blood Pressure and Hypertension Studies
- Peroxisome Proliferator-Activated Receptors
- Nutritional Studies and Diet
- Biomarkers in Disease Mechanisms
- Antioxidant Activity and Oxidative Stress
- Cardiovascular Disease and Adiposity
- Cardiovascular Health and Disease Prevention
- Fatty Acid Research and Health
- Diabetes Treatment and Management
- Cardiac Health and Mental Health
- Systemic Lupus Erythematosus Research
- Diet and metabolism studies
- Medication Adherence and Compliance
MultiMedica
2016-2025
University of Milan
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Pharmac
2007-2024
Novo Nordisk (United Kingdom)
2024
Institute for Health Metrics and Evaluation
2024
University of Washington
1992-2024
Mylan (Switzerland)
2024
University Hospital Leipzig
2024
University of Pisa
2023
The ESC/EAS Guidelines represent the views of ESC and EAS, were produced after careful consideration scientific medical knowledge, evidence available at time their publication.The EAS is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when...
ABI : ankle–brachial (blood pressure) index ABPM : ambulatory blood pressure monitoring ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin-converting enzyme inhibitor ACS : acute coronary syndromes ADVANCE : Diabetes and Vascular disease: PreterAx
<h2>Summary</h2><h3>Background</h3> Regularly updated data on stroke and its pathological types, including their incidence, prevalence, mortality, disability, risk factors, epidemiological trends, are important for evidence-based care planning resource allocation. The Global Burden of Diseases, Injuries, Risk Factors Study (GBD) aims to provide a standardised comprehensive measurement these metrics at global, regional, national levels. <h3>Methods</h3> We applied GBD 2019 analytical tools...
Addendum I. SCORE charts with high-density lipoprotein-cholesterol II.Practical approach to reach low-density goal III.Inhibitors and inducers
The Task Force for the Management of Dyslipidaemias European Society Cardiology (ESC) and Atherosclerosis (EAS) Developed with special contribution Assocciation Cardiovascular Prevention & Rehabilitation (EACPR) ABI : ankle-brachial index
The first aim was to critically evaluate the extent which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. second provide guidance for screening treatment of FH, in order prevent coronary heart disease (CHD).Of theoretical estimated prevalence 1/500 heterozygous <1% are diagnosed most countries. Recently, direct a Northern European general population approximately 1/200 with FH. All reported studies document failure achieve recommended LDL cholesterol targets large...
AimsThe aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, advise on screening for elevated plasma Lp(a), desirable levels, and therapeutic strategies.
Abstract
Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity genetic defects clinical phenotype HoFH, availability new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia European Atherosclerosis Society (EAS) critically...
Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment cardiovascular disease. The effect lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on risk events or diabetes is unknown.We used genetic scores consisting independently inherited variants genes encoding and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; target statins) as instruments to randomly assign 112,772...
Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy acid treatment in long-term involving patients with hypercholesterolemia who receiving guideline-recommended statin therapy.We conducted a randomized, controlled trial atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to LDL cholesterol level at...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance testing treating elevated levels, considers its inclusion global risk estimation. Epidemiologic genetic studies involving hundreds thousands individuals strongly support a causal continuous association between concentration outcomes different ethnicities; is factor...